<DOC>
	<DOCNO>NCT00555607</DOCNO>
	<brief_summary>The aim project study pathogenetic mechanism severe asthma compare mechanisms chronic obstructive pulmonary disease ( COPD ) order test hypothesis severe asthma COPD develop similar chronic degenerative change .</brief_summary>
	<brief_title>Longitudinal Assessment Clinical Course BIOmarkers Severe Chronic AIRway Disease</brief_title>
	<detailed_description>The BIOAIR project focus sub-group asthma patient suffer severe difficult-to-control asthma , frequent asthma exacerbation ( 'attacks ' ) . This sub-group asthma patient consist around 10 % asthma patient , account half total community cost asthma . It yet unknown patient much severely ill compare majority asthma patient control disease . No adequate treatment yet establish . The BIOAIR study initiate order find mechanisms underlie severe asthma . Since change occur severe asthma similar patient chronic obstructive lung disease ( COPD ) , group COPD patient include study well . A group control mild-to-moderate asthma include comparative reason .</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>For patient : 1 . The patient understand study procedure agree participate sign consent form . 2 . The patient male female , least 18 year age 80 year age entry study ( screen visit ) . For patient asthma ( group 1 2 ) 1 . The patient history intermittent persistent symptom wheeze , breathlessness , chest tightness cough . The diagnosis asthma must confirm specialist pulmonary medicine . 2 . The patient fulfil one several follow criterion reversible airway obstruction , document last 5 year study screen visit : 1 . An increase FEV1 9 % predict ( improvement 200 mL ) administration 4 puff 100 microg salbutamol doseaerosol inhaler via spacer , additional inhalation four puff 20 microg ipratropium bromide ( Atrovent ) administer large volume spacer . 2 . A mean diurnal variation Peak Expiratory Flow ( PEF ) 15 % 4 days/week least 2 week , calculate follow equation : ( high PEFlowest PEF ) /mean PEF 3 . An increase FEV1 least 400 mL course prednisolone 0.5mg/kg/day 14 day . 4 . In patient FEV1 70 % predict , demonstrate bronchial hyperresponsiveness histamine , methacholine , isocapnic hyperventilation , exercise indirect challenge ( accord establish local method ) . 3 . The patient nonsmoker total smoke history le 5 pack year . In case patient smoking , must less 10 cigarette day asthma must start smoking . Specific patient mild moderate asthma ( group 1 ) 1 . The patient stable disease minimal symptom , exacerbation hospitalisation last year . 2 . The patient us inhale steroid regularly , 800 microg/day budesonide beclomethasone , 500 microg/day fluticasone . 3 . The patient us prescribe shortacting beta agonist need . 4 . The patient require treatment longacting betaagonists . Specific patient severe asthma ( group 2 ) 1 . The patient specialist treatment least one year . 2 . The patient require continuous treatment high dos inhale steroid . If patient take oral steroid , inhale dose steroid must 1600 microg/day budesonide beclomethasone , 800 microg/day fluticasone equivalent . In case patient take oral steroid , inhale dose steroid must 800 microg/day budesonide beclomethasone , 400 microg/day fluticasone equivalent . 3 . The patient require continuous treatment long act inhale betaagonists oral theophylline , document least one year . 4 . The patient experience least one asthma exacerbation previous year . Specific patient COPD ( group 3 ) 1 . The diagnosis COPD must make specialist pulmonary medicine . The patient may may chronic symptom ( cough , sputum production , dyspnoea ) . 2 . The patient FEV1/Forced Vital Capacity ( FVC ) ratio le 70 % . 3 . The patient 's post bronchodilator FEV1 value 30 % le 80 % predict . 4 . The patient smoking history 15 pack year , either current exsmoker . 5 . The patient display negative reversibility test inhale bronchodilator define increase FEV1 le 9 % predict ( improvement le 200 mL ) administration 4 puff 100 microg salbutamol doseaerosol inhaler via spacer , four puff 20 microg ipratropium bromide ( Atrovent ) administer large volume spacer . 6 . The patient history asthma . 7 . The patient current allergy , show negative skinprick test . 8 . The patient use inhaled steroid range 8001600 microg/day ( budesonide equivalent ) least 3 month prior study . General exclusions 1 . The patient pregnant . 2 . The patient recent history incapacitate psychotic disorder . 3 . The patient current recent past abuser alcohol illicit drug . 4 . The patient history malignancy , know positive HIV , state consider interfere study conduct scientific interpretation . 5 . The patient read comprehend write material , opinion investigator , reason unlikely understand follow study procedure . 6 . The patient mentally legally incapacitate preventing inform consent obtain . Exclusions pulmonary disorder 1 . The patient unable perform acceptable spirometry , peak flow measurement and/or complete diary card satisfactory way period visit 1 visit 3B ( optimisation period prednisolone/placebo trial ) . If patient unable use electronic Peak Flow meters/Diary card , acceptable use ordinary mechanical meter ( e.g . MiniWright ) together paper version diary card . Patients unable use mechanical meter paper diary card period visit 1 3B enter followup year . 2 . The patient , addition asthma COPD , pulmonary disorder accord investigator would interfere study procedure scientific evaluation ( e.g . tuberculosis ) . 3 . The patient suffer chronic hypercapnic respiratory failure indicate elevated pCO2 ( &gt; 47 mm Hg 6,25 kPa ) . In case doubt confirm pulse oximetry blood gas sampling . Exclusions medication 1 . The patient receive immunosuppressant corticosteroid ( i.e. , methotrexate , gold , troleandomycin , cyclosporin experimental antiinflammatory drug ) within three month study entry . 2 . The patient currently undergo immunotherapy . 3 . The patient receive chronic oxygen therapy . Specific exclusion criterion patient asthma ( group 1 &amp; 2 ) 1 . The patient smoke five ( 5 ) pack year . Specific exclusion criterion patient mild asthma ( group 1 ) 1 . The patient require treatment longacting betaagonists . Specific exclusion criterion patient severe asthma ( group 2 ) 1 . The patient treat high dos inhale steroid ( see ) . 2 . The patient exacerbation asthma last year . 3 . The patient require treatment longacting betaagonists theophylline document one year . Specific exclusion criterion patient COPD ( group 3 ) 1 . The patient history asthma confirm specialist pulmonary medicine . Specific exclusion criterion bronchoscopy ( group ) 1 . The patient severe exacerbation asthma require high dos oral steroid last three ( 3 ) month . 2 . The patient severe exacerbation COPD require intensive outpatient treatment hospitalisation last three ( 3 ) month . 3 . The patient three severe exacerbation asthma COPD last year . 4 . The patient display 10 % fall FEV1 2 minute inhalation 0.9 % saline ( induction sputum visit 2 ) . 5 . The patient show sign uncontrolled disease last three day , e.g . patient require four puffs/day rescue medication baseline use last three day . ( In case criterion 14 meet , patient may reschedule bronchoscopy two week time . The start oral prednisolone intervention postpone number day pass bronchoscopy ) . 6 . If patient otherwise qualified bronchoscopy receive 6 mg per kg BW lidocaine preparation procedure , bronchoscopy must terminate continued day . 7 . Patients experience severe bronchoconstriction adverse reaction previous attempt perform bronchoscopy . 8 . The patient postbronchodilator FEV1 &lt; 40 % predict . 9 . Do start proceed bronchoscopy : Transcutaneous oxygen saturation pulseoximeter &lt; 90 % ( despite give oxygen nasal cannula saturation &lt; 94 % ) Heart frequency &gt; 130 Heart rhythm disturbance . Specific exclusion criterion induce sputum ( group ) 1 . A postbronchodilator ( administration 4 puff 100 microg salbutamol doseaerosol inhaler via spacer ) FEV1 percent predict less 60 % , absolute value less 1.0 L. 2 . A peak flow variability 30 % previous four day . 3 . Patients display 15 % fall FEV1 2 minute inhalation saline ( 0.9 % NaCl ) induction sputum.. 4 . Patients experience severe bronchoconstriction adverse reaction previous attempt induce sputum .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>asthma</keyword>
	<keyword>COPD</keyword>
	<keyword>severe</keyword>
	<keyword>control</keyword>
	<keyword>mild</keyword>
	<keyword>biomarker</keyword>
	<keyword>exacerbation</keyword>
</DOC>